{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:07:13Z","timestamp":1786975633322,"version":"build-2736575974"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Opioid tapering has been associated with negative consequences, such as increased overdoses and mental health needs. Tapering could also alter use of health care services and worsen care of comorbid conditions through disruption in primary care.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate tapering of stable long-term opioid therapy (LTOT) and subsequent health care service use and chronic condition care.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective cohort study was conducted from January 1, 2008, to December 31, 2019. Data analysis was performed from July 9, 2020, to December 9, 2022. Data from the Optum Labs Data Warehouse, which contains deidentified retrospective administrative claims data and linked electronic health record data for commercial and Medicare Advantage enrollees, were used. Adults aged 18 years or older prescribed stable doses of LTOT at 50 morphine milligram equivalents or more per day during a 12-month baseline period were included, including subcohorts with hypertension or diabetes.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Opioid tapering, with 15% or more relative reduction in mean daily dose in 6 overlapping periods during 6 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Emergency department visits, hospitalizations, primary care and specialist visits, antihypertensive or antiglycemic medication adherence, and blood pressure and hemoglobin A\n 1c<\/jats:sub>\n levels during up to 12 months\u2019 follow-up. Covariates included sociodemographic characteristics, comorbidities, health care use, and chronic condition control.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 113\u202f604 patients (60\u202f764 [53.5%] women; mean [SD] age, 58.1 [11.8] years) prescribed LTOT, 41\u202f207 had hypertension and 23\u202f335 had diabetes; in all cohorts, approximately half were women, and half were aged 50 to 65 years. In the overall cohort, tapering was associated with more emergency department visits (adjusted incidence rate ratio [aIRR], 1.19; 95% CI, 1.16-1.21) and hospitalizations (aIRR, 1.16; 95% CI, 1.12-1.20), with similar magnitude associations in the hypertension and diabetes subcohorts. Tapering was associated with fewer primary care visits in the overall cohort (aIRR, 0.95; 95% CI, 0.94-0.96) and hypertension subcohort (aIRR, 0.98; 95% CI, 0.97-0.99). For the hypertension or diabetes subcohorts, tapering was associated with reduced medication adherence (hypertension: aIRR, 0.60; 95% CI, 0.59-0.62; diabetes: aIRR, 0.69; 95% CI, 0.67-0.71) and small increases in diastolic blood pressure and hemoglobin A\n 1c<\/jats:sub>\n level.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients prescribed LTOT, opioid tapering was associated with more emergency department visits and hospitalizations, fewer primary care visits, and reduced antihypertensive and antidiabetic medication adherence. These outcomes may represent unintended negative consequences of opioid tapering for policy makers and clinicians to consider.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.55101","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:04:39Z","timestamp":1675767879000},"page":"e2255101","source":"Crossref","is-referenced-by-count":28,"title":["Association Between Opioid Tapering and Subsequent Health Care Use, Medication Adherence, and Chronic Condition Control"],"prefix":"10.1001","volume":"6","author":[{"given":"Elizabeth M.","family":"Magnan","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, University of California, Davis, Sacramento"},{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Tancredi","sequence":"additional","affiliation":[{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento"},{"name":"Department of Pediatrics, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guibo","family":"Xing","sequence":"additional","affiliation":[{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Agnoli","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of California, Davis, Sacramento"},{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jerant","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of California, Davis, Sacramento"},{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Fenton","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of California, Davis, Sacramento"},{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"issue":"15","key":"zoi221560r1","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"zoi221560r3","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnz152","article-title":"The national imperative to align practice and policy with the actual CDC opioid guideline.","author":"Darnall","year":"2019","journal-title":"Pain Med"},{"issue":"5","key":"zoi221560r4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jama.2021.11013","article-title":"Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids.","volume":"326","author":"Agnoli","year":"2021","journal-title":"JAMA"},{"key":"zoi221560r5","doi-asserted-by":"publisher","first-page":"m283","DOI":"10.1136\/bmj.m283","article-title":"Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation.","volume":"368","author":"Oliva","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"zoi221560r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2613","article-title":"Association between opioid dose variability and opioid overdose among adults prescribed long-term opioid therapy.","volume":"2","author":"Glanz","year":"2019","journal-title":"JAMA Netw Open"},{"key":"zoi221560r7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2019.05.001","article-title":"Opioid medication discontinuation and risk of adverse opioid-related health care events.","volume":"103","author":"Mark","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"zoi221560r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108664","article-title":"\u201cI felt like I had a scarlet letter\u201d: recurring experiences of structural stigma surrounding opioid tapers among patients with chronic, non-cancer pain.","volume":"222","author":"Benintendi","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi221560r9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/ejp.2014.18.issue-6","article-title":"Communicating about opioids for chronic pain: a qualitative study of patient attributions and the influence of the patient-physician relationship.","volume":"18","author":"Matthias","year":"2014","journal-title":"Eur J Pain"},{"issue":"1","key":"zoi221560r10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11606-019-05227-9","article-title":"Opioid taper is associated with subsequent termination of care: a retrospective cohort study.","volume":"35","author":"Perez","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi221560r11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1370\/afm.1398","article-title":"Influence of primary care on breast cancer outcomes among Medicare beneficiaries.","volume":"10","author":"Roetzheim","year":"2012","journal-title":"Ann Fam Med"},{"issue":"7","key":"zoi221560r12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7326\/0003-4819-159-7-201310010-00003","article-title":"Primary care utilization and colorectal cancer incidence and mortality among Medicare beneficiaries: a population-based, case-control study.","volume":"159","author":"Ferrante","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi221560r13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpain.2018.09.001","article-title":"Patients\u2019 experience with opioid tapering: a conceptual model with recommendations for clinicians.","volume":"20","author":"Henry","year":"2019","journal-title":"J Pain"},{"issue":"11","key":"zoi221560r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16271","article-title":"Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008-2017.","volume":"2","author":"Fenton","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi221560r16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/pm\/pnaa470","article-title":"Longitudinal dose trajectory among patients tapering long-term opioids.","volume":"22","author":"Fenton","year":"2021","journal-title":"Pain Med"},{"key":"zoi221560r17","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"zoi221560r18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/acem.13140","article-title":"Identification of emergency department visits in Medicare administrative claims: approaches and implications.","volume":"24","author":"Venkatesh","year":"2017","journal-title":"Acad Emerg Med"},{"issue":"1","key":"zoi221560r20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1377\/hlthaff.12.1.162","article-title":"Impact of socioeconomic status on hospital use in New York City.","volume":"12","author":"Billings","year":"1993","journal-title":"Health Aff (Millwood)"},{"issue":"11","key":"zoi221560r21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.18553\/jmcp.2016.22.11.1224","article-title":"A systematic review of insulin adherence measures in patients with diabetes.","volume":"22","author":"Stolpe","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"6719","key":"zoi221560r22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/bmj.300.6719.230","article-title":"Analysis of serial measurements in medical research.","volume":"300","author":"Matthews","year":"1990","journal-title":"BMJ"},{"issue":"1","key":"zoi221560r23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"7","key":"zoi221560r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6928","article-title":"Access to primary care clinics for patients with chronic pain receiving opioids.","volume":"2","author":"Lagisetty","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi221560r26","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.pec.2019.02.015","article-title":"The impact of patient-physician alliance on trust following an adverse event.","volume":"102","author":"Shoemaker","year":"2019","journal-title":"Patient Educ Couns"},{"issue":"7","key":"zoi221560r27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in hypertension.","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ Res"},{"issue":"1","key":"zoi221560r28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/dmt.13.62","article-title":"Effective interventions to improve medication adherence in type 2 diabetes: a systematic review.","volume":"4","author":"Williams","year":"2014","journal-title":"Diabetes Manag (Lond)"},{"key":"zoi221560r19","volume-title":"Guide to Prevention Quality Indicators: Hospital Admission for Ambulatory Care Sensitive Conditions","author":"Agency for Healthcare Research and Quality","year":"2002"},{"key":"zoi221560r24","volume-title":"Overview of US Hospital Stays in 2016: Variation by Geographic Region","author":"Freeman","year":"2018"},{"key":"zoi221560r2","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. April 9, 2019. Accessed December 10, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes"},{"key":"zoi221560r14","unstructured":"Optum Labs. Data from: Optum Labs and Optum Labs Data Warehouse (OLDW) Descriptions and Citation. 2020. Accessed January 5, 2023. https:\/\/www.optumlabs.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801014\/magnan_2023_oi_221560_1674764118.85094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:04:45Z","timestamp":1675767885000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55101","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]}}}